Evidence-Based Nutraceutical Intervention for Subclinical Neurological States
The Problem
Subclinical neurological impairments affect millions — yet no nutraceutical intervention has undergone rigorous clinical validation for these indications.
Subclinical MCI
Subclinical mild cognitive impairment affects nearly 1 in 5 adults globally — the largest unaddressed prodromal stage before clinical diagnosis.
Post-Viral Fatigue
Subclinical chronic fatigue prevalence has doubled post-pandemic. Up to 10% of infections induce lasting neurobiological dysfunction.
Burnout-Related CNS Strain
Neurobiologically measurable burnout — marked by HPA-axis dysregulation and prefrontal hypoactivation — rose 84% in the past decade.
Validated Interventions
No nutraceutical product on the market has undergone double-blind clinical validation for subclinical neurological indications.
Federal institutions are calling for stricter scientific verification. No validated nutraceutical intervention exists for these indications.
A Life Science Approach
This is our envisaged solution to the problem outlined above: a transdisciplinary framework targeting subclinical neurological dysfunction at its biochemical roots — not symptoms, but mechanisms.
Neuroscience
Top-down approach targeting subclinical dysfunction in neurotransmitter synthesis, neuroinflammation, and mitochondrial CNS supply.
Nutrition Science
Bottom-up biochemical intervention using bioavailable precursors and cofactors to correct subclinical nutritional deficits driving neurological impairment.
Clinical Validation
Double-blind longitudinal trials in subclinical populations — MCI, CFS, burnout — with multi-modal neurobiological endpoints.
Three Formulations. One Day.
Circadian-aligned nutraceutical intervention — each formulation targets distinct subclinical mechanisms of its time window.
The three formulations are circadian-aligned: complementary mechanisms across morning, midday, and evening reduce overlap while converging on shared subclinical endpoints — one integrated system, not three isolated products.
Morning
Mitochondrial Recovery & Dopaminergic Restoration
Primary Mechanisms
- 1Mitochondrial dysfunction correction & ATP synthesis
- 2Catecholaminergic deficit restoration
- 3AMPA-receptor hyposensitization reversal
Midday
Cholinergic Deficit Correction & Neuroplasticity Support
Primary Mechanisms
- 1Subclinical acetylcholine deficiency correction
- 2Phospholipid membrane repair & BDNF upregulation
- 3Cerebral hypoperfusion & thyroid hypofunction support
Evening
GABAergic Stabilization & Neuroregeneration
Primary Mechanisms
- 1GABAergic inhibition deficit & serotonin precursor supply
- 2Circadian rhythm dysregulation & sleep architecture restoration
- 3Antioxidant synthesis & neurotrophic factor upregulation
Six Ingredient Classes
All formulations are built exclusively from these evidence-based classes.
Minerals & Trace Elements
Essential cofactors for CNS enzymatic processes, neurotransmitter synthesis, and mitochondrial electron transport chain function.
Vitamins
Critical for one-carbon methylation cycles, myelin sheath integrity, antioxidant defense, and neurohormone synthesis.
Amino Acids
Direct biosynthetic precursors to dopaminergic, serotonergic, cholinergic, and GABAergic pathways — the substrate layer of neurotransmission.
Lipids
Structural components of neuronal membranes, synaptic vesicle formation, and myelination — essential for signal transduction fidelity.
Vitaminoids & Compounds
Mitochondrial electron chain cofactors, redox regulators, and antioxidant network components targeting subclinical oxidative stress.
Plant & Mushroom Extracts
Adaptogenic and neurotrophic phytocompounds with documented mechanisms for NGF/BDNF induction and HPA-axis modulation in subclinical populations.
Let's improve the trajectory of human existence together. The core values of the company are:
- Impactfulness first (bioavailable ingredients, synergetic mechanisms & empirically proven);
- One team, one world (professional as well as interpersonal coherence & corporate social responsibility);
- Reign of velocity (rapid movement and evolution by carefully building a strong foundation);
And everything is covered under the umbrella of science, because we are technocrats.
Rigorous Research Design
Double-blind, longitudinal crossover trials in subclinical populations — with multi-modal neurobiological endpoints across four phased prevention levels (primary through tertiary).
Psychometrics
Standardized subclinical screening: MCI severity, fatigue indices, burnout staging, neuropsychiatric symptom rating scales
Blood & Urine
Neurotransmitter precursors, catecholamines, acetylcholine, GABA, inflammatory markers, mitochondrial function proxies
EEG
Resting-state and task-evoked cortical activity — theta/alpha power as biomarkers for subclinical cognitive impairment
fMRI
Functional connectivity in prefrontal cortex, hippocampus, and default mode network — structural correlates of subclinical decline
Study Phases
Subclinical-first design — escalating from primary prevention to borderline clinical populations
Pilot Study
Healthy adults with subclinical risk markers, 50% dosage, primary prevention design
Subclinical Population
Screened MCI/CFS/burnout cohort, secondary prevention, 75% dosage
Clinical Extension
Diagnosed borderline population, secondary prevention — moderating disease course, 100% dosage
Replication
Tertiary prevention post-convalescence; independent verification in subclinical cohort, 50% dosage
Transdisciplinary Team
Psychology, medicine, pharmacy, and business — united by the mission to improve human cognition.
Max Vogel
Founder & CEO
Clinical Psychology (M.Sc.) & Organizational Development
Product formulation, research design, psychometric support, strategic leadership
LinkedInDr. Maxim Kots
Chief Scientific & Medical Officer
Clinical Development & Medical Affairs (M.D.)
Scientific processing, study execution, neurobiological diagnostics, safety regulations
LinkedInAnton Schiller
Chief Operating & Developing Officer
Pharmacy (State License) & Quality Assurance
Pharmaceutical realization, contract manufacturing, supply chain, digitalization
LinkedInScientific Advisors
Dr. Stefan Schulreich
Neuroscience
Dr. Shahrouz Jafarzadeh
Statistics
Nicole Langer
Psychometrics
Mentors & Collaborators
Prof. Dr. Meike Watzlawik
Psychology & Organizational Development
Christian Walker
Microbiology & Neuro-Startups
Dr. Eva-Maria Hempe
Health & Sales strategy
Deutsches Institut für Ernährungsforschung (DIfE)
Study implementation, recruitment, bioavailability
Pensatech Pharma
Drug delivery & formulation consulting
Market Opportunity
The nutraceutical neurological market is driven by ageing populations, post-viral syndromes, and rising demand for evidence-based subclinical prevention. The headline figures below are all stated as of 2022 reporting.
Global market size (2022)
CAGR, 2022 baseline
Top German competitor revenue (2022)
Strategic outlook
Digital health
Potential synergies with digital phenotyping and adherence tools are under exploration — no commitments to specific products yet.
Pharmaceuticals
Future combinations or sequencing with pharmacotherapy may be evaluated where evidence and regulation align — exploratory only at this stage.
Microbiome
Product concepts linking gut–brain axes and targeted microbiome support remain prospective R&D directions, not current claims.
Subclinical MCI Population
Adults with early cognitive markers not yet meeting diagnostic thresholds — the largest undertreated prodromal stage before Alzheimer's
Post-Viral & Fatigue Disorders
Long-COVID, CFS, burnout-related neuro-fatigue, and related cohorts with measurable mitochondrial and neuroimmunological dysfunction but limited pharmacological options
Prevention-Oriented Aging Adults
Individuals with first subclinical biomarkers seeking evidence-based delay of neurodegeneration before irreversible clinical decline
Why Neurotrition Wins
Scientific Legitimacy
Every ingredient is backed by peer-reviewed mechanistic evidence. No proprietary blends — full transparency on dosages and rationale.
Synergistic Formulation
Ingredients are co-selected for pharmacokinetic compatibility and biochemical synergy — not stacked additively but designed as a system.
Clinical Validation
Double-blind crossover trials in subclinical populations — our endpoint data goes beyond self-reporting to include EEG and fMRI biomarkers.
Patent-Protected IP
Proprietary circadian-aligned delivery system and formulation ratios protected by IP — creating durable defensibility against fast-followers.